A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03000452 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene